[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"breast-cancer-hrher2--early-stage\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:breast-cancer-hrher2--early-stage":41},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":24,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":4},"100630214",false,"NCT07484763","Predicting Recurrence in HR+\u002FHER2- Early Breast Cancer","A Single-Center Retrospective Study to Develop a Nomogram for Predicting Recurrence in HR+\u002FHER2- Early Breast Cancer Using Real-World Data","Inclusion Criteria:\n\n* Histopathologically confirmed invasive breast ductal carcinoma or lobular carcinoma;\n* Molecular subtype of HR+\u002FHER2- (ER ≥ 10%, and HER2 immunohistochemistry 0\u002F1+ or 2+ without amplification confirmed by FISH);\n* Received standardized surgical treatment and postoperative adjuvant (or preoperative neoadjuvant) endocrine therapy;\n* Complete follow-up data available.\n\nExclusion Criteria:\n\n* Presence of distant metastasis (Stage IV) at diagnosis\n* Male breast cancer\n* Missing key clinicopathological data or loss to follow-up\n* HER2 immunohistochemistry 3+ or 2+ with amplification confirmed by FISH\n* Triple-negative breast cancer","FEMALE","18 Years",{"count":18,"type":19},500,"ESTIMATED","OBSERVATIONAL","Hormone receptor-positive\u002Fhuman epidermal growth factor receptor 2-negative (HR+\u002FHER2-) breast cancer constitutes approximately 70% of all breast cancer cases. Although early-stage patients generally have favorable outcomes following standard surgery and adjuvant endocrine therapy, long-term follow-up data reveal a distinct \"bimodal\" or \"long-tail\" recurrence pattern, with risks persisting for decades. Recent landmark trials (e.g., NATALEE, MonarchE) have established that combining CDK4\u002F6 inhibitors with endocrine therapy significantly improves invasive disease-free survival (iDFS) in high-risk populations. However, the stringent enrollment criteria of these randomized controlled trials may not fully capture the heterogeneity of real-world patients. Reliance on binary cut-off values (e.g., nodal status alone) risks misclassifying biologically high-risk individuals with low anatomical burden, leading to either undertreatment or overtreatment. There is an urgent clinical need for a multidimensional, individualized risk assessment tool to guide escalated therapy decisions.",[23],"Breast Cancer, HR+\u002FHER2- Early-Stage",[25,26,27,28],"Breast Cancer","HR+\u002FHER2-","Nomogram","Recurrence","NOT_YET_RECRUITING","2026-03-16",{"date":32,"type":33},"2026-03-20","ACTUAL",{"date":35,"type":19},"2026-04-01",{"date":37,"type":19},"2027-04-01",{"name":39,"class":40},"Shengjing Hospital","OTHER",""]